Explore psychedelic drug development via our Q1'25 šŸŽÆ Bullseye Chart.
You are currently viewing Clearmind Medicine Announces Share-Based Payment for the Company’s Consultants

Clearmind Medicine Announces Share-Based Payment for the Company’s Consultants

Tel Aviv, Israel / Vancouver, Canada, July 17, 2023 (GLOBE NEWSWIRE) — Ā Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (ā€œClearmindā€ or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has issued 17,899 common shares in the capital of the Company (“Shares”) in lieu of the final payment ofĀ $10,000, startingĀ May 1st 2022, to consultants of the Company.

In addition, the Company has issued restricted stock units (“RSUS”) for additional consultant in lieu of payment ofĀ $5,000.

All Shares will only be subjected to those restrictions designated in applicable securities laws.

AboutĀ ClearmindĀ Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The companyā€™s intellectual portfolio currently consists of fourteen patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed on Nasdaq and the Canadian Securities Exchange under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol ā€œCWY.ā€

For further information visit:Ā www.clearmindmedicine.comĀ or contact:

Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US:Ā CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This press release contains ā€œforward-looking statementsā€ within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as ā€œexpects,ā€ ā€œanticipates,ā€ ā€œintends,ā€ ā€œplans,ā€ ā€œbelieves,ā€ ā€œseeks,ā€ ā€œestimatesā€ and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its clinical trial collaborations, and the potential therapeutic benefit of its product candidates. Forward-looking statements are not historical facts, and are based upon managementā€™s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that managementā€™s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Companyā€™s reports filed from time to time with the Securities and Exchange Commission (ā€œSECā€), including, but not limited to, the risks detailed in the Companyā€™s annual report on Form 20-F filed with the SEC on February 6, 2023. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

Source link

Leave a Reply

Subscribe to Our Free Newsletter